Gang liu | Cancer | Best Researcher Award

Posted on by PencisLeave a Comment on Gang liu | Cancer | Best Researcher Award

Prof Gang liu | Cancer | Best Researcher Award

Gansu Provincial Center for Disease Control and Prevention | China

Author Profile

Scopus

Gang Liu: Pioneer in Radiobiology and Preventive Medicine āš›ļø

EARLY ACADEMIC PURSUITS šŸŽ“

Gang Liu began his academic journey at Lanzhou University, where he pursued a PhD in preventive medicine. His graduation in 1997 marked the beginning of a career dedicated to understanding the impacts of radiation on health. His academic training in preventive medicine provided the foundation for his future contributions to radiobiology and public health, particularly in the context of disease control and prevention.

PROFESSIONAL ENDEAVORS šŸ¢

After obtaining his PhD, Gang Liu embarked on a distinguished career at the Gansu Provincial Center for Disease Control and Prevention. His professional focus has been on the intersection of radiobiology, immunology, and tumor screening. In 2019, his registration as a health physicist signaled a significant milestone. He became the technical lead for a groundbreaking study on low-dose dose-effect relationships, a critical area in radiation therapy and safety. His expertise in radiation protection and therapy has earned him a prominent position within the medical research community.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCERšŸ§¬

Gang Liu's research primarily revolves around radiobiology and radiation protection in therapy. His technological advancements in biological dose estimation are considered cutting-edge within China and recognized internationally. One of his significant contributions was revising the 2011 IAEA Manual based on findings from his studies on radiological sensitivity and dose rates. This revision, coupled with his publications in the FASEB Journal, has made Liu a leading figure in radiation science. His work in chromosomal aberration analysis and developing noninvasive techniques for early-stage cancer screening underscores his innovative approach to medical research.

IMPACT AND INFLUENCE šŸŒ

Gang Liu's influence extends beyond national borders. His research on radiological sensitivity and dose rates, especially in the context of cancer screening and radiation therapy, has set new benchmarks in the field. The international recognition of his work, particularly his advancements in biological dose estimation and contributions to global radiation protection protocols, underscores his importance in radiobiology. His work is used by institutions worldwide to improve radiation safety standards and enhance cancer diagnostic techniques.

ACADEMIC CITATIONS šŸ“š

His pioneering research has been published in prestigious journals such as the FASEB Journal, one of the top international platforms for scientific contributions. The citations of his work in radiological sensitivity, chromosomal aberration analysis, and cancer screening techniques reflect his deep impact on the scientific community, with his methods influencing both practical applications in healthcare and further research.

LEGACY AND FUTURE CONTRIBUTIONS šŸ”¬

Gang Liuā€™s legacy will likely be defined by his leadership in advancing radiation protection technology and cancer screening techniques. As an innovator in radiological health, his influence will continue to grow through future contributions to radiation therapy safety, noninvasive cancer detection, and international health standards. His ongoing work in exploring new methods for biological dose estimation will further establish his standing as a key figure in the evolution of radiation medicine.

NOTABLE PUBLICATIONSĀ šŸ“‘

"Study of Low-Dose Radiation Workers Ionizing Radiation Sensitivity Index and Radiation Dose-Effect Relationship"Ā 

  • Authors: Liu, G., Zhang, R., Li, Y., Liu, Y.Y., Zhang, X.
  • Journal: Health Physics
  • Year: 2022

"Revision of cytogenetic dosimetry in the IAEA manual 2011 based on data about radio-sensitivity and dose-rate findings contributing"Ā 

  • Authors:Liu, G.
  • Journal: FASEB Journal
  • Year: 2022

"Thyroid dose assessments due to inhalation of 131I for nuclear medicine workers"

  • Authors: Liu, G., Li, Y., Zhang, H., Niu, L.M., Zhang, R.
  • Journal: Frontiers in Public Health
  • Year: 2022

"Study of Indicators for Early and Rapid Diagnosis of Radiation Injury Is the Most Important in Patients With Cancer During Radiotherapy"

  • Authors: Liu, G., Niu, L.-M., Wang, L.-Q., Liu, Y.-Y., Zhang, R.
  • Journal: Dose-Response
  • Year: 2020

"Chromosomal aberration analysis: Novel noninvasive techniques for early-stage cancer screening"

  • Authors: Liu, G.
  • Journal: Clinica Chimica Acta
  • Year: 2024

Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Posted on by PencisLeave a Comment on Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Dr. Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Gregorio Maranon University Hospital | Spain

Author Profile

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Since 2017, I have been dedicated to advancing the field of pharmacogenetics, beginning as a research assistant and progressing through to postdoctoral researcher at the Pharmacogenetics Laboratory of the Gregorio MaraĆ±Ć³n General University Hospital. My journey started with foundational research roles and evolved into leadership positions within various pharmacogenomic studies.

PROFESSIONAL ENDEAVORS

Starting as a research assistant, I gradually transitioned to roles as a predoctoral and postdoctoral researcher, accumulating invaluable experience and expertise in pharmacogenetics. My work has been primarily focused on pharmacogenomic studies in diverse medical areas such as colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases.

CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACOGENMICS AND PERSONALIZED MEDICINE

Throughout my career, I have actively contributed to 21 publications in pharmacogenomics, with a particular emphasis on colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases. Of these publications, I served as the first author for 14, showcasing my significant contributions to the field. Notably, my doctoral thesis in 2020 centered on intestinal inflammatory disease, underscoring my commitment to advancing knowledge in this area.

IMPACT AND INFLUENCE

My contributions have not gone unnoticed, as evidenced by receiving the AEFA (Spanish Clinical Laboratory Association) award for quality and innovation in 2019. Additionally, my research has been recognized through presentations at 20 national and international conferences, including 5 oral communications. I have been honored with the best oral communication award at three conferences, highlighting the impact of my work.

ACADEMIC CITES

My research has contributed to the academic discourse, with citations in various publications, further validating the significance and influence of my work in pharmacogenetics awards and related fields.

LEGACY AND FUTURE CONTRIBUTIONS

As an active member of the Spanish Society of Pharmacogenetics awards and the Spanish Association of Human Genetics, I continue to contribute to the advancement and dissemination of knowledge in these critical areas of public health. My ongoing commitment to research and collaboration ensures that my contributions will continue to shape the future of pharmacogenetics.

NOTABLE PUBLICATIONS

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children 2023(3)

Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease 2023(7)

Hongmeng Su | Gene Regulations |Ā Best Researcer Award

Posted on by PencisLeave a Comment on Hongmeng Su | Gene Regulations |Ā Best Researcer Award

Dr. Hongmeng Su | Gene Regulations and Epigenetics |Ā  Best Researcer Award

Southeast University | China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Hongmeng Su embarked on an academic journey marked by a strong foundation in bioengineering, which laid the groundwork for subsequent achievements. Graduating with a Bachelor of Engineering in Bioengineering from Nanjing Agriculture University in 2019, Su's early academic pursuits showcased a dedication to biological sciences and a burgeoning interest in research.

PROFESSIONAL ENDEAVORS

Transitioning seamlessly from undergraduate to graduate studies, Su pursued a Master of Science in Biology at the School of Life Science and Technology, Southeast University, from 2019 to 2021. This period not only honed Su's research skills but also provided a platform for academic growth and exploration in the field of biology.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE REGULATIONS AND EPIGENETICS

Su's contributions to the field of medical genetics and developmental biology are underscored by a multifaceted approach to understanding the molecular mechanisms driving hepatocellular carcinogenesis. Through meticulous research endeavors, Su has delved into the intricate interplay between non-coding RNA, transcription factors, and carcinogenesis, shedding light on key pathways implicated in cancer progression and metastasis.

IMPACT AND INFLUENCE

Su's research findings have garnered recognition and accolades, affirming the significance of their contributions to the scientific community. Notably, Su's report on the combined analysis of m6A and m5C RNA methylation modulators received honorable mention at the 10th Member Congress and Academic Seminar of Jiangsu Genetic Association, showcasing the impact of their work on hepatocellular carcinoma prognosis.

ACADEMIC CITATIONS

Su's scholarly endeavors have contributed to the advancement of knowledge in medical genetics, developmental biology, and cancer research. Their publications serve as a testament to their dedication to scientific inquiry and the dissemination of impactful findings within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As a Ph.D. candidate at the Department of Medical Genetics & Developmental Biology, School of Medicine, Southeast University, Su's legacy is characterized by a commitment to unraveling the complexities of hepatocellular carcinogenesis. Armed with a diverse skill set encompassing molecular and cellular experimentation, bioinformatics analysis, and statistical modeling, Su is poised to make enduring contributions to the field of cancer biology and beyond. Their future endeavors hold the promise of further elucidating the molecular underpinnings of cancer progression, informing novel therapeutic strategies, and ultimately, advancing human health.

Notable Publications

TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p 2021(35)

ETV4 facilitates angiogenesis in hepatocellular carcinoma by upregulating MMP14 expression

Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma